SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at UBS Group

UBS Group initiated coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report report published on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

A number of other equities analysts also recently commented on SABS. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. Leerink Partners started coverage on shares of SAB Biotherapeutics in a report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, Guggenheim initiated coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.68 on Wednesday. The company has a fifty day simple moving average of $3.70 and a two-hundred day simple moving average of $2.79. The company has a market cap of $175.20 million, a price-to-earnings ratio of -1.19 and a beta of 0.58. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.38. As a group, equities analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. HB Wealth Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $618,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter worth approximately $32,000. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the third quarter valued at approximately $30,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $40,000. Finally, Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $8,847,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.